Title of article
Jaap Verweij, Paolo G Casali, John Zalcberg, Axel LeCesne, Peter Reichardt, Jean-Yves Blay, Rolf Issels, Allan van Oosterom, Pancras CW Hogendoorn, Martine Van Glabbeke, Rossella Bertulli, Ian Judson for the EORTC Soft Tissue and Bone Sarcoma Group, the I
Author/Authors
Jaap Verweij، نويسنده , , Paolo G Casali، نويسنده , , John Zalcberg، نويسنده , , Axel LeCesne، نويسنده , , Peter Reichardt، نويسنده , , Jean-Yves Blay، نويسنده , , Rolf Issels، نويسنده , , Allan Van Oosterom، نويسنده , , Pancras CW Hogendoorn، نويسنده , , Martine Van Glabbeke، نويسنده , , Rossella Bertulli، نويسنده , , Ian Judson، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2004
Pages
8
From page
1127
To page
1134
Abstract
Background
Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST.
Methods
946 patients were randomly allocated ima
Journal title
The Lancet
Serial Year
2004
Journal title
The Lancet
Record number
587055
Link To Document